BACLOFEN - Generic Drug Details

What are the generic sources for baclofen and what is the scope of freedom to operate?

Baclofen is the generic ingredient in eight branded drugs marketed by Strides Pharma Intl, Amneal, Heritage, Maia Pharms Inc, Pharmobedient, Rubicon Research, Piramal Critical, Metacel Pharms Llc, Ani Pharms, Azurity, Ucb Inc, Andas 5 Holding, Aurobindo Pharma Ltd, Hibrow Hlthcare, Impax, Ivax Sub Teva Pharms, Lannett Co Inc, Mankind Pharma, Micro Labs, Northstar Hlthcare, Oxford Pharms, Ph Health, Regcon Holdings, Rising, Somerset Theraps Llc, Sun Pharm Inds Inc, Teva, Unichem, Usl Pharma, Watson Labs, Yiling, Zydus Lifesciences, and Novartis, and is included in forty-nine NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baclofen has fourteen patent family members in eight countries.

There are twenty-one drug master file entries for baclofen. Sixty-three suppliers are listed for this compound.

Summary for BACLOFEN

International Patents:	14
US Patents:	8
Tradenames:	8
Applicants:	33
NDAs:	49
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	63
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	130
Patent Applications:	7,596
Drug Prices:	Drug price trends for BACLOFEN
Drug Sales Revenues:	Drug sales revenues for BACLOFEN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BACLOFEN
What excipients (inactive ingredients) are in BACLOFEN?	BACLOFEN excipients list
DailyMed Link:	BACLOFEN at DailyMed

See drug prices for BACLOFEN

See drug sales revenues for BACLOFEN

Recent Clinical Trials for BACLOFEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Adnan Imtiaj Rahul	PHASE2
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal	PHASE4
KAZM Pharmaceuticals Inc.	PHASE3

See all BACLOFEN clinical trials

Pharmacology for BACLOFEN

Drug Class	gamma-Aminobutyric Acid-ergic Agonist
Mechanism of Action	GABA A Agonists GABA B Agonists

Medical Subject Heading (MeSH) Categories for BACLOFEN

GABA-B Receptor Agonists

Muscle Relaxants, Central

Anatomical Therapeutic Chemical (ATC) Classes for BACLOFEN

M03BX	Other centrally acting agents
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

Paragraph IV (Patent) Challenges for BACLOFEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FLEQSUVY	Oral Suspension	baclofen	25 mg/5 mL	215602	1	2022-05-20
OZOBAX DS	Oral Solution	baclofen	5 mg/5 mL	208193	1	2021-07-26

US Patents and Regulatory Information for BACLOFEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rubicon Research	BACLOFEN	baclofen	SOLUTION;ORAL	214445-001	Dec 6, 2024		RX	No	No
Ivax Sub Teva Pharms	BACLOFEN	baclofen	TABLET;ORAL	072234-001	Jul 21, 1988	AB	RX	No	No
Sun Pharm Inds Inc	BACLOFEN	baclofen	TABLET;ORAL	077862-002	Aug 14, 2006		DISCN	No	No
Amneal	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	091193-001	May 3, 2016	AP	RX	No	No
Unichem	BACLOFEN	baclofen	TABLET;ORAL	212067-002	Jul 9, 2020	AB	RX	No	No
Amneal	BACLOFEN	baclofen	INJECTABLE;INTRATHECAL	091193-002	May 3, 2016	AP	RX	No	No

Expired US Patents for BACLOFEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	6,024,981
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	6,024,981
Novartis	LIORESAL	baclofen	TABLET;ORAL	017851-003	Jan 20, 1982	3,471,548
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	6,221,392
Novartis	LIORESAL	baclofen	TABLET;ORAL	017851-001	Approved Prior to Jan 1, 1982	3,471,548
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	6,221,392

International Patents for BACLOFEN

Country	Patent Number	Title	Estimated Expiration
Japan	2022544901
Canada	3036356	SUSPENSIONS ET DILUANTS POUR LE METRONIDAZOLE ET LE BACLOFENE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN)
China	114450002
World Intellectual Property Organization (WIPO)	2023055457
European Patent Office	3509592	SUSPENSIONS ET DILUANTS POUR LE MÉTRONIDAZOLE ET LE BACLOFÈNE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN)
World Intellectual Property Organization (WIPO)	2018049184

Baclofen Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Baclofen, a gamma-aminobutyric acid (GABA) derivative, functions as a skeletal muscle relaxant. Its primary indication is the treatment of spasticity associated with conditions such as multiple sclerosis, spinal cord injuries, and cerebral palsy. The global baclofen market is characterized by a mix of generic competition and ongoing research into novel delivery methods and expanded therapeutic applications.

What is the Current Market Size and Projected Growth for Baclofen?

The global baclofen market was valued at approximately $800 million in 2022. Projections indicate a compound annual growth rate (CAGR) of 4.5% to 5.5% over the next five years, reaching an estimated $1.1 billion by 2028. This growth is driven by an increasing prevalence of neurological disorders requiring spasticity management and the sustained demand for cost-effective generic formulations. The market is segmented by formulation (oral tablets, oral solutions, and intrathecal pumps) and by indication (multiple sclerosis, spinal cord injury, cerebral palsy, and others). Oral tablets constitute the largest market segment due to their accessibility and established efficacy.

What are the Key Drivers of Market Demand?

Several factors are propelling demand for baclofen:

• Rising Incidence of Neurological Disorders: The global increase in conditions like multiple sclerosis and spinal cord injuries directly translates to a higher patient population requiring spasticity management. According to the World Health Organization, an estimated 2.8 million people worldwide live with multiple sclerosis [1].
• Aging Global Population: An aging demographic is more susceptible to conditions that can lead to spasticity, such as stroke and degenerative neurological diseases, further augmenting market demand.
• Cost-Effectiveness of Generic Baclofen: The availability of numerous generic baclofen products after patent expirations of originator drugs makes the treatment accessible to a broader patient base, particularly in emerging economies. This price advantage is a significant market driver.
• Advancements in Drug Delivery Systems: While oral formulations dominate, innovation in drug delivery, such as the development of more sophisticated intrathecal pump systems for severe spasticity, is contributing to market value and patient outcomes. These systems offer targeted delivery and reduced systemic side effects.

Who are the Major Manufacturers and Competitors in the Baclofen Market?

The baclofen market is highly competitive, with a significant number of generic manufacturers. Key players include:

• Teva Pharmaceutical Industries Ltd.: A leading global generic pharmaceutical company with a broad portfolio including baclofen.
• Amneal Pharmaceuticals LLC: Another major generic drug manufacturer with a presence in the spasticity treatment market.
• Mylan N.V. (now part of Viatris Inc.): A prominent supplier of generic and specialty pharmaceuticals.
• Sun Pharmaceutical Industries Ltd.: An Indian multinational pharmaceutical company with a substantial generic drug offering.
• Impax Laboratories, Inc. (now part of Amneal Pharmaceuticals): Historically a significant player in the generics market.

The competitive landscape is largely defined by pricing strategies, manufacturing capacity, and the ability to secure distribution channels. Market entry barriers for generic formulations are moderate, primarily involving regulatory approvals and established supply chains.

What are the Key Patent Expirations and Their Impact on Market Competition?

The patent for the original R&D baclofen formulation has long expired, leading to widespread generic availability. For example, the original U.S. patent for Lioresal (baclofen) expired decades ago. This has resulted in a highly fragmented market where price competition is a primary determinant of market share. The absence of strong, compound-specific patent protection for the basic baclofen molecule means that innovation in this space primarily focuses on:

• Formulation enhancements: Developing extended-release versions or novel delivery mechanisms.
• New indications: Investigating baclofen's efficacy for conditions beyond spasticity.
• Combination therapies: Exploring its use alongside other therapeutic agents.

However, these secondary innovations often face challenges in achieving significant market penetration against established generic alternatives due to cost considerations and the need for extensive clinical trials to prove superiority.

What are the Regulatory Hurdles and Considerations for Baclofen Products?

Regulatory approval processes for baclofen, particularly for generic versions, are rigorous and vary by region.

• United States: The Food and Drug Administration (FDA) requires Abbreviated New Drug Applications (ANDAs) for generic versions, demonstrating bioequivalence to the reference listed drug.
• European Union: The European Medicines Agency (EMA) oversees the authorization of medicines, requiring comprehensive data on quality, safety, and efficacy for both innovative and generic products.
• Other Regions: National regulatory bodies in countries like Canada, Australia, and Japan have their own approval pathways, often aligning with major international standards.

Key considerations include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to strict GMP standards to ensure product quality and consistency.
• Bioequivalence Studies: Generic manufacturers must prove their product performs identically to the reference drug in terms of absorption, distribution, metabolism, and excretion.
• Labeling and Post-Market Surveillance: Compliance with updated labeling requirements and ongoing monitoring for adverse events are critical.

The approval process can take several months to over a year, depending on the complexity of the submission and the workload of the regulatory agency.

What is the Financial Trajectory and Profitability Outlook for Baclofen Manufacturers?

The financial trajectory for baclofen manufacturers is largely dictated by the dynamics of the generic drug market.

• Established Generic Manufacturers: Companies with large-scale manufacturing capabilities and efficient supply chains can achieve profitability through high-volume sales of low-margin products. Their financial success hinges on operational efficiency and market access.
• Specialty and Intrathecal Products: Manufacturers focusing on specialized formulations, such as those for intrathecal delivery, may command higher profit margins due to the complexity of the technology and the smaller, more specialized patient population they serve. However, the overall market size for these niche products is smaller.
• R&D Investment: While the basic baclofen molecule has limited patentability, companies investing in new delivery systems or exploring novel indications may see potential for higher returns, though these investments carry higher risk and longer development timelines.

The overall profitability in the standard oral baclofen market is moderate due to intense price competition. Companies must manage their cost of goods sold meticulously and maintain strong relationships with wholesalers and pharmacy benefit managers to secure market share.

What are the Emerging Trends and Future Opportunities in the Baclofen Market?

Several emerging trends and future opportunities could shape the baclofen market:

• Personalized Medicine Approaches: Research into genetic markers that influence response or side effects to baclofen could lead to more tailored treatment strategies. While early-stage, this could influence future prescribing patterns.
• Expanded Indications Research: Ongoing studies exploring baclofen's efficacy in treating conditions beyond spasticity, such as alcohol dependence, chronic pain, and certain psychiatric disorders, represent potential new market avenues. For example, studies have investigated baclofen for the treatment of alcohol use disorder, showing promise in reducing cravings and relapse rates [2].
• Enhanced Delivery Technologies: Development of novel drug delivery systems, including long-acting injectable formulations or improved oral formulations offering better patient compliance and reduced dosing frequency, could create differentiated products.
• Focus on Patient-Reported Outcomes: Increasing emphasis on real-world evidence and patient-reported outcomes may drive demand for therapies that demonstrably improve quality of life beyond mere symptom reduction.

What are the Key Risks and Challenges Facing the Baclofen Market?

The baclofen market faces several significant risks and challenges:

• Intense Price Competition: The large number of generic manufacturers leads to aggressive pricing, eroding profit margins for standard oral formulations.
• Regulatory Scrutiny: Increasing regulatory oversight on drug quality, manufacturing processes, and marketing practices can lead to compliance costs and potential product recalls.
• Availability of Alternative Therapies: The development of newer, potentially more effective, or better-tolerated treatments for spasticity or other investigated indications could diminish baclofen's market share.
• Reimbursement Pressures: Healthcare payers continuously seek to control costs, which can lead to reimbursement limitations or preference for lower-cost alternatives, impacting market access.
• Supply Chain Disruptions: Global supply chain vulnerabilities, as evidenced in recent years, can affect the availability of raw materials and finished products, leading to shortages.

Key Takeaways

The baclofen market is characterized by a mature generic segment driven by demand from neurological conditions and an aging population. Key manufacturers compete primarily on price, with profitability in oral formulations being moderate. Future growth potential lies in research into expanded indications and innovative drug delivery systems, though these ventures involve significant R&D investment and face competitive pressures from established generics and emerging therapies. Regulatory compliance and navigating reimbursement landscapes are critical for all market participants.

Frequently Asked Questions

1. What is the typical pricing range for generic baclofen tablets? Generic baclofen tablet prices can range from $0.10 to $0.50 per tablet, depending on the dosage strength, quantity purchased, and the specific manufacturer. Prices can vary significantly between different pharmacies and distributors.

2. Are there any significant ongoing clinical trials for new uses of baclofen? Yes, ongoing clinical trials are investigating baclofen for conditions including alcohol use disorder, chronic pain syndromes, and Tourette syndrome. Results from these trials could lead to new therapeutic applications.

3. How does baclofen's efficacy compare to other muscle relaxants? Baclofen is primarily used for spasticity related to central nervous system disorders. Its efficacy is comparable to other GABAergic agents and centrally acting muscle relaxants for spasticity, but it has a different profile for other types of muscle pain or spasms.

4. What are the main side effects associated with baclofen use? Common side effects include drowsiness, dizziness, weakness, fatigue, and confusion. Less common but more serious side effects can include respiratory depression, seizures, and hallucinations.

5. Is baclofen a controlled substance? No, baclofen is not a controlled substance in most jurisdictions. It is a prescription medication due to its potential for side effects and the need for medical supervision.

Citations

[1] World Health Organization. (n.d.). Multiple sclerosis. Retrieved from https://www.who.int/news-room/fact-sheets/detail/multiple-sclerosis [2] National Institute on Alcohol Abuse and Alcoholism. (n.d.). Baclofen for Alcohol Use Disorder. Retrieved from https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/baclofen-alcohol-use-disorder